TLDR Paychex reported Q1 2026 revenue of $1.54B, up 17% year-over-year. Adjusted EPS rose 5% to $1.22, beating expectations, while GAAP EPS fell 10%. Operating expenses increased 29% to $998M, driven by Paycor acquisition. Management raised the fiscal 2026 revenue growth outlook to 16.5–18.5%. Shares closed at $126.76 on September 30, down 1.38% for the [...] The post Paychex Inc. ($PAYX) Stock: Q1 2026 Earnings Beat Forecasts but Rising Costs Weigh appeared first on CoinCentral.TLDR Paychex reported Q1 2026 revenue of $1.54B, up 17% year-over-year. Adjusted EPS rose 5% to $1.22, beating expectations, while GAAP EPS fell 10%. Operating expenses increased 29% to $998M, driven by Paycor acquisition. Management raised the fiscal 2026 revenue growth outlook to 16.5–18.5%. Shares closed at $126.76 on September 30, down 1.38% for the [...] The post Paychex Inc. ($PAYX) Stock: Q1 2026 Earnings Beat Forecasts but Rising Costs Weigh appeared first on CoinCentral.

Paychex Inc. ($PAYX) Stock: Q1 2026 Earnings Beat Forecasts but Rising Costs Weigh

2025/10/01 17:51
Okuma süresi: 3 dk
Bu içerikle ilgili geri bildirim veya endişeleriniz için lütfen [email protected] üzerinden bizimle iletişime geçin.

TLDR

  • Paychex reported Q1 2026 revenue of $1.54B, up 17% year-over-year.
  • Adjusted EPS rose 5% to $1.22, beating expectations, while GAAP EPS fell 10%.
  • Operating expenses increased 29% to $998M, driven by Paycor acquisition.
  • Management raised the fiscal 2026 revenue growth outlook to 16.5–18.5%.
  • Shares closed at $126.76 on September 30, down 1.38% for the day.

Paychex Inc. (NASDAQ: PAYX) closed at $126.76 on September 30, down 1.38% ahead of its Q1 2026 earnings release.

Paychex, Inc. (PAYX)

The company posted revenue of $1.54 billion, a 17% year-over-year increase, surpassing Wall Street estimates of $1.53 billion. Adjusted diluted EPS came in at $1.22, up 5% from $1.16 last year, and slightly above the consensus of $1.21. On a GAAP basis, EPS dropped 10% to $1.06.

 

Operating income margin stood at 35.2%, while the adjusted margin was 40.7%, reflecting expense pressures tied to integration and expansion initiatives.

Revenue Growth Across Segments

Management Solutions, the company’s largest segment, generated $1.2 billion in revenue, a 21% increase, underscoring demand for payroll and HR services. PEO and Insurance Solutions contributed $329 million, a modest 3% rise, as growth in the agency side was slowed by workers’ comp rate pressures. Interest on funds held for clients rose 27% to $48 million, benefiting from higher interest rates.

The Paycor integration also supported growth, driving new cross-selling opportunities with retained clients and accelerating synergy targets.

Rising Costs and Margin Impact

Expenses climbed 29% to $998 million in the quarter, largely linked to Paycor-related costs. The company cited disruptions as it works to align go-to-market strategies, though it expects efficiencies to improve. Despite top-line growth, concentrated losses in the small business sector, particularly firms shutting down, added pressure.

Still, management highlighted strong demand for PEO services, mid-single-digit employee growth, and innovations in AI-driven HR tools designed to improve client experience and productivity.

Strong Cash Flow and Shareholder Returns

Paychex reported $718 million in operating cash flow and returned $549 million to shareholders through dividends and buybacks. The company maintained $1.7 billion in cash and investments, offset by $5 billion in borrowings. Its 12-month rolling return on equity stood at 40%, reflecting efficient capital use.

Fiscal 2026 Outlook Raised

Looking ahead, Paychex guided fiscal 2026 revenue growth of 16.5% to 18.5%. Management Solutions is expected to grow 20% to 22%, while PEO and Insurance Solutions are forecast at 6% to 8%. Interest on funds held for clients should deliver $190 million to $200 million. Adjusted EPS is projected to increase 9% to 11%, supported by an operating margin of about 43% and an effective tax rate of 24% to 25%.

Market Context

Despite strong fundamentals, Paychex shares have lost 7.7% year-to-date compared with the S&P 500’s 13.7% gain. Over the past year, the stock is down 2.9%, underperforming the index’s 16% rise. Analysts note estimate revisions have trended lower, resulting in a Zacks Rank #4 (Sell), suggesting the stock may underperform near-term.

For investors, Paychex’s growth trajectory remains attractive, but rising expenses and competitive pressures could limit upside until Paycor integration benefits fully materialize.

The post Paychex Inc. ($PAYX) Stock: Q1 2026 Earnings Beat Forecasts but Rising Costs Weigh appeared first on CoinCentral.

Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

CME Group to launch options on XRP and SOL futures

CME Group to launch options on XRP and SOL futures

The post CME Group to launch options on XRP and SOL futures appeared on BitcoinEthereumNews.com. CME Group will offer options based on the derivative markets on Solana (SOL) and XRP. The new markets will open on October 13, after regulatory approval.  CME Group will expand its crypto products with options on the futures markets of Solana (SOL) and XRP. The futures market will start on October 13, after regulatory review and approval.  The options will allow the trading of MicroSol, XRP, and MicroXRP futures, with expiry dates available every business day, monthly, and quarterly. The new products will be added to the existing BTC and ETH options markets. ‘The launch of these options contracts builds on the significant growth and increasing liquidity we have seen across our suite of Solana and XRP futures,’ said Giovanni Vicioso, CME Group Global Head of Cryptocurrency Products. The options contracts will have two main sizes, tracking the futures contracts. The new market will be suitable for sophisticated institutional traders, as well as active individual traders. The addition of options markets singles out XRP and SOL as liquid enough to offer the potential to bet on a market direction.  The options on futures arrive a few months after the launch of SOL futures. Both SOL and XRP had peak volumes in August, though XRP activity has slowed down in September. XRP and SOL options to tap both institutions and active traders Crypto options are one of the indicators of market attitudes, with XRP and SOL receiving a new way to gauge sentiment. The contracts will be supported by the Cumberland team.  ‘As one of the biggest liquidity providers in the ecosystem, the Cumberland team is excited to support CME Group’s continued expansion of crypto offerings,’ said Roman Makarov, Head of Cumberland Options Trading at DRW. ‘The launch of options on Solana and XRP futures is the latest example of the…
Paylaş
BitcoinEthereumNews2025/09/18 00:56
Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

The post Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves appeared on BitcoinEthereumNews.com. The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee, America’s Health Insurance Plans said Wednesday, Sept. 17, 2025. In this photo is a free flu and Covid-19 vaccine shots available sign, CVS, Queens, New York. (Photo by: Lindsey Nicholson/Universal Images Group via Getty Images) UCG/Universal Images Group via Getty Images The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee. The announcement by America’s Health Insurance Plans (AHIP), which includes CVS Health’s Aetna, Humana, Cigna, Centene and an array of Blue Cross and Blue Shield plans as members, comes ahead of the first meeting of the reconstituted Advisory Committee on Immunization Practices, which now has new members chosen by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a vaccine critic. “Health plans are committed to maintaining and ensuring affordable access to vaccines,” AHIP said in a statement Wednesday. “Health plan coverage decisions for immunizations are grounded in each plan’s ongoing, rigorous review of scientific and clinical evidence, and continual evaluation of multiple sources of data.” The move by AHIP is good news for millions of Americans at a time of year when they flock to drugstores, pharmacies, physician’s offices and outpatient clinics to get their seasonal flu and Covid shots. Kennedy’s changes to U.S. vaccine policy have created confusion across the country over whether certain vaccines long covered by insurance would continue to be. AHIP has now provided some clarity for millions of Americans. “Health plans will continue to cover all ACIP-recommended immunizations that were recommended as of September 1, 2025, including updated formulations of the COVID-19 and influenza vaccines, with no cost-sharing…
Paylaş
BitcoinEthereumNews2025/09/18 03:11
US, UK, Canada Launch Operation Atlantic to Tackle Crypto Scams

US, UK, Canada Launch Operation Atlantic to Tackle Crypto Scams

Law enforcement agencies from the United States, United Kingdom, and Canada have launched Operation Atlantic, a joint effort to combat rising crypto scams and protect
Paylaş
Coinlaw2026/03/17 22:11